{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:43:42Z","timestamp":1782459822441,"version":"3.54.5"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1704,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>Limited data exist for the use of alemtuzumab (AL) induction in liver transplantation (LT) recipients. We compared the outcomes of hepatitis C virus-negative LT recipients who received AL induction followed by tacrolimus and mycophenolate mofetil without steroids to cohort who received no AL induction, tacrolimus, and a steroid taper. Fifty-five AL-induced recipients were compared to 85 non-AL-induced recipients with similar characteristics. Two-year patient survival (80% versus 88.2%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0665) and graft survival (76.4% versus 82.4%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.1792) were not significantly different between the AL and non-AL groups, respectively. Other outcomes, including acute rejection (20% versus 30.3%), renal dysfunction (creatinine levels: 1.3 \u00b10.3 versus 1.4 \u00b1 0.6 mg\/dL), and immunosuppressant monotherapy (29.1% versus 44.3%), were not significantly different between the AL and non-AL groups, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.05). The number of rejection episodes (12 versus 42, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02) and the number of patients with new-onset hypertension (3 versus 15, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03) were lower in the AL group, although the incidence of all posttransplant infections was higher with AL (63.6% versus 44.3%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03), primarily because of an increase in viral infections. In conclusion, a steroid-free AL induction regimen was associated with less hypertension and rejection but with more infectious complications; thus, the overall benefit of AL induction in LT recipients is called into question. Liver Transpl 17:32-37, 2011. \u00a9 2011 AASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.22180","type":"journal-article","created":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T23:21:54Z","timestamp":1283296914000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":35,"title":["Alemtuzumab induction in non-hepatitis C positive liver transplant recipients"],"prefix":"10.1097","volume":"17","author":[{"given":"Josh","family":"Levitsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Thudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Ison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Abecassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20250124","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.intimp.2004.09.026","article-title":"Prope tolerancethe future of organ transplantation from the laboratory to the clinic.","volume":"5","author":"Calne","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"R2-6-20250124","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/00007890-199911270-00032","article-title":"Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.","volume":"68","author":"Calne","year":"1999","journal-title":"Transplantation"},{"key":"R3-6-20250124","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MOT.0b013e32832b45d0","article-title":"Alemtuzumab and liver transplantation: a review.","volume":"14","author":"Dhesi","year":"2009","journal-title":"Curr Opin Organ Transplant"},{"key":"R4-6-20250124","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1432-2277.2006.00343.x","article-title":"The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.","volume":"19","author":"Magliocca","year":"2006","journal-title":"Transpl Int"},{"issue":"suppl 3","key":"R5-6-20250124","first-page":"397","article-title":"Alemtuzumab facilitates prednisone free immunosuppression in kidney transplant recipients with no early rejection.","volume":"2","author":"Stuart","year":"2002","journal-title":"Am J Transplant"},{"key":"R6-6-20250124","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/01.TP.0000065192.53065.50","article-title":"Preliminary experience with Campath 1H (C1H) in intestinal and liver transplantation.","volume":"75","author":"Tzakis","year":"2003","journal-title":"Transplantation"},{"key":"R7-6-20250124","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/01.TP.0000116562.15920.43","article-title":"Preliminary experience with alemtuzumab (Campath-1H) and low dose tacrolimus immunosuppression in adult liver transplantation.","volume":"77","author":"Tzakis","year":"2004","journal-title":"Transplantation"},{"key":"R8-6-20250124","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.transproceed.2004.12.157","article-title":"The impact of Campath 1H induction in adult liver allotransplantation.","volume":"37","author":"Tryphonopoulos","year":"2005","journal-title":"Transplant Proc"},{"key":"R9-6-20250124","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/01.TP.0000142674.78268.01","article-title":"Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus.","volume":"78","author":"Marcos","year":"2004","journal-title":"Transplantation"},{"key":"R10-6-20250124","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.510250328","article-title":"Banff schema for grading liver allograft rejection: an international consensus document.","volume":"25","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R11-6-20250124","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0140-6736(05)77739-4","article-title":"Prope tolerance, perioperative Campath 1H, and low-dose cyclosporine monotherapy in renal allograft recipients.","volume":"351","author":"Calne","year":"1998","journal-title":"Lancet"},{"key":"R12-6-20250124","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1399-0012.2008.00816.x","article-title":"Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab.","volume":"22","author":"Alcaide","year":"2008","journal-title":"Clin Transplant"},{"key":"R13-6-20250124","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.tp.0000189713.14993.db","article-title":"Campath-1H induction and incidence of infectious complications in adult renal transplantation.","volume":"81","author":"Malek","year":"2006","journal-title":"Transplantation"},{"key":"R14-6-20250124","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1399-3062.2006.00149.x","article-title":"Cryptococcosis in liver and kidney transplant recipients receiving antithymocyte globulin or alemtuzumab.","volume":"9","author":"Silveira","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"R15-6-20250124","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1086\/510388","article-title":"Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab humanized monoclonal CD-52 antibody.","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22180","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201101000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:04:42Z","timestamp":1737738282000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201101000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.22180","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}